Total buying$00 buys
LGND
LIGAND PHARMACEUTICALS INC
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 09/24 to 10/24.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$1.52M6 sells
Net open-market−$1.52MBuying minus selling
Active insiders1Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 06, 2026
Open-market transaction mix · 6 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
| Oct 2026 | 0 | 6 | 0 | $0 | $1.52M | -$1.52M |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (1)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- RA-$1.5M
LGND transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
LGNDLIGAND PHARMACEUTICALS INC | Reardon AndrewCLO · SECY | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
LGNDLIGAND PHARMACEUTICALS INC | Reardon AndrewCLO · SECY | S · sale10b5-1 detectedSEC filing ↗ | -$5.23kView disclosure → | |
LGNDLIGAND PHARMACEUTICALS INC | Reardon AndrewCLO · SECY | S · sale10b5-1 detectedSEC filing ↗ | -$72.1kView disclosure → | |
LGNDLIGAND PHARMACEUTICALS INC | Reardon AndrewCLO · SECY | S · sale10b5-1 detectedSEC filing ↗ | -$123kView disclosure → | |
LGNDLIGAND PHARMACEUTICALS INC | Reardon AndrewCLO · SECY | S · sale10b5-1 detectedSEC filing ↗ | -$467kView disclosure → | |
LGNDLIGAND PHARMACEUTICALS INC | Reardon AndrewCLO · SECY | S · sale10b5-1 detectedSEC filing ↗ | -$599kView disclosure → | |
LGNDLIGAND PHARMACEUTICALS INC | Reardon AndrewCLO · SECY | S · sale10b5-1 detectedSEC filing ↗ | -$251kView disclosure → | |
LGNDLIGAND PHARMACEUTICALS INC | Reardon AndrewCLO · SECY | M · exercise10b5-1 detectedSEC filing ↗ | $17.7kView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period8transactionstxns
- S · Open-market sells · dominant6 · 75%
- M · Option exercise2 · 25%
Activity by reported role
A joint filing can contribute to multiple rolesCLO8
SECY8
Reported Holdings After
Separated by insider, security, and ownership type
Reardon AndrewCommon Stock · Direct
31,854Oct 02, 2026
Reardon AndrewEmployee Stock Option (right to buy) · Direct
29,104Oct 02, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 24 → Oct 24
LessMore
LIGAND PHARMACEUTICALS INC Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at LIGAND PHARMACEUTICALS INC?
Reardon Andrew.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Reardon Andrew reported a sale on Oct 02, 2026 valued at $5.23k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $1,520,345.86. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.